Please login to the form below

Not currently logged in
Email:
Password:

Richard Chin joins board of ImmunoCellular Therapeutics

Adds drug development experience as company looks to advance brain tumour vaccine

Former CEO of the non-profit pharma firm OneWorld Health Dr Richard Chin has joined the board of directors at ImmunoCellular Thereapeutics.

Chin, who currently serves on the adjunct faculty of the University of California, San Francisco School of Medicine, will also become chair of the compensation committee at ImmunoCellular – a US-based clinical-stage company developing immune-based therapies for the treatment of cancer.

“His extensive experience in drug development will be valuable as the company advances its phase II clinical trial of ICT-107,” said ImmunoCellular's chairman Dr John Yu, referencing the company's cancer vaccine currently in development for the brain tumour glioblastoma multiforme.

Chin spent left OneWorld Health in 2011 after spending three years leading the organisation, which aims to develop new treatments for neglected diseases. It is largely funded by the Bill and Melinda Gates Foundation.

Prior to this role, he was president and CEO of biopharma Oxigene from 2006 to 2008 and he has also held senior roles at Elan and Genentech.

19th March 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...

Infographics